Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 16;12(4):490.
doi: 10.3390/ani12040490.

Serum Proteomic Changes in Dogs with Different Stages of Chronic Heart Failure

Ahmet Saril  1 , Meric Kocaturk  1 , Kazumi Shimada  2 , Akiko Uemura  3 , Emel Akgün  4 , Pinar Levent  1 , Ahmet Tarik Baykal  4 , Alberto Muñoz Prieto  5 , Carlos Fernando Agudelo  6 , Ryou Tanaka  2 , Jose Joaquin Ceron  7 , Jorgen Koch  8 , Zeki Yilmaz  1
Affiliations

Serum Proteomic Changes in Dogs with Different Stages of Chronic Heart Failure

Ahmet Saril et al. Animals (Basel). .

Abstract

MMVD, the most common cause of CHF in dogs, is a chronic disease with variable clinical signs, with some patients remaining asymptomatic while others develop CHF. Here, we aimed to evaluate serum proteins by proteomic analysis in dogs at different stages of CHF due to MMVD, and proteome behaviors after conventional treatment. A total of 32 dogs were divided equally into four groups-stage A (healthy/controls), stage B2 (asymptomatic), stage C and stage D (symptomatic)-according to the ACVIM consensus. Serum proteomes were evaluated using LC/MS-based label-free differential proteome analysis. The study revealed 157 different proteins; 11 were up- and 21 down-regulated in dogs with CHF compared to controls. In stage B2 dogs, angiotensinogen (AGT) was up-regulated, but immunoglobulin iota chain-like, lipopolysaccharide-binding protein, and carboxypeptidase (CPN) were down-regulated. In stage C dogs, complement C3 (C3) and inter-alpha-trypsin inhibitor heavy chain were up-regulated, but hemopexin, and actin-cytoplasmic-1 (ACT-1) were down-regulated. In stage D dogs, AGT was up-regulated, whereas tetranectin, paraoxonase-1, adiponectin and ACT-1 were down-regulated. A decrease in CPN, C3 and AGT and an increase in ACT-1 were observed after treatment of dogs in stage C. This pilot study identified that dogs at different stages of CHF show different serum protein composition which has potential to be biomarker for diagnose and treatment monitorization.

Keywords: ACVIM; dogs; heart disease; mitral valve disease; proteomic.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any financial or personal relationships that could inappropriately influence or bias the content of the paper.

Figures

Figure 1
Figure 1
String interaction analysis of up- and down-regulated serum proteins in dogs with CHF compared to healthy controls. Legend: This figure was created using the open-source web application www.string-db.org (accessed on 3 September 2021).
Figure 2
Figure 2
Network representation of Go term of serum proteins which showed the differences at statistically significant level in dogs with CHF compared to healthy controls. Legend: Short name of up- and down-regulated proteins and their biological functions are shown in the orange and green boxes, respectively. When the proteins have the same biological functions, light green is changed to dark green. This figure was created with the Euler diagram using the open-source GOnet web application (https://tools.dice-database.org/GOnet/, accessed on 3 September 2021).
See this image and copyright information in PMC

References

    1. Egenvall A., Bonnett B.N., Olson P., Hedhammar A. Gender, age, breed and distribution of morbidity and mortality in insured dogs in Sweden during 1995 and 1996. Vet. Rec. 2000;146:519–525. doi: 10.1136/vr.146.18.519. - DOI - PubMed
    1. Corcoran B.M., Black A., Anderson H., McEwan J.D., French A., Smith P., Devine C. Identification of surface morphologic changes in the mitral valve leaflets and chordae tendineae of dogs with myxomatous degeneration. Am. J. Vet. Res. 2004;65:198–206. doi: 10.2460/ajvr.2004.65.198. - DOI - PubMed
    1. Häggström J., Pedersen D.H., Kvart C. New insights into degenerative mitral valve disease in dogs. Vet. Clin. N. Am. Small Anim. Pract. 2004;34:1209–1226. doi: 10.1016/j.cvsm.2004.05.002. - DOI - PubMed
    1. Borgarelli M., Savarino P., Crosara S., Santilli R.A., Chiavegato D., Poggi M., Bellino C., La Rosa G., Zanatta R., Haggstrom J., et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J. Vet. Intern. Med. 2008;22:120–128. doi: 10.1111/j.1939-1676.2007.0008.x. - DOI - PubMed
    1. Boswood A., Häggström J., Gordon S.G., Wess G., Stepien R.L., Oyama M.A., Keene B.W., Bonagura J., MacDonald K.A., Patteson M., et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial. J. Vet. Intern. Med. 2016;30:1765–1779. doi: 10.1111/jvim.14586. - DOI - PMC - PubMed

LinkOut - more resources